Plain-English translation of NCT07059767 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new nasal spray medication called to see if it can help prevent asthma symptoms from getting worse when you catch a common cold virus (rhinovirus). Researchers want to understand whether this treatment can protect your airways and keep your asthma under control during a viral infection. Some participants will receive the medication and others will receive a placebo (a spray with no active ingredient) to compare how well the treatment works.
Many people with asthma find that catching a cold makes their asthma symptoms flare up and become harder to control. This medication is being tested to see if it can help prevent that kind of worsening, which could make life easier and safer for people with asthma during cold season.
You likely qualify if…
You likely don't qualify if…
You will visit the study center where you'll receive either the nasal spray or a placebo spray. Then researchers will intentionally expose you to a harmless form of rhinovirus (cold virus) to see how your asthma responds and whether the treatment helps prevent symptoms from developing. The study team will monitor your symptoms and lung function closely throughout the trial to keep you safe and gather data on how well the medication works.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United Kingdom
Phase
Testing effectiveness
Sponsor
Ethris GmbH
Collaborators
VirTus Respiratory Research Ltd
Enrollment target
~50 participants
Started
June 2025
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dr. Philipp Schreppel
Ethris GmbH
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.